Terms ending in 2031
Every in-force patent on Gilead Sciences, Inc.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,673,929 | 4,6-DI- and 2,4,6-Trisubstituted Quinazoline Derivatives and Pharmaceutical Compositions Useful for Treating Viral Infections In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,884,030 | Inhibitors of Flaviviridae Viruses In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 9,321,753 | Inhibitors of Flaviviridae Viruses In force · Medium confidence | Gilead Sciences, Inc. | In force | Medium confidence | |
| US 8,729,089 | PYRIDO(3,2-D)PYRIMIDINES Useful for Treating Viral Infections In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,513,298 | Inhibitors of Flaviviridae Viruses In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,999,969 | Anti-Rsv Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,263,612 | Viral Inhibitors In force · High confidence | Katholieke Universiteit Leuven | In force | High confidence | |
| US 9,637,512 | Nucleoside Phosphoramidates In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,524,764 | Inhibitors of Flaviviridae Viruses In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,513,186 | Antiviral compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| 30 more term ends in 2031 · Pro | |||||
10 of 40 patents shown. Soonest term end first, then patent number.
Pro members see all 40.
39 of these are in force and held by Gilead Sciences, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.